Walking away is a legitimate outcome of diligence. It is not a diligence failure, it is not a wasted process, and it is not a personal reflection on either the buyer or the seller. Most non-licensee buyers of California treatment businesses close the first target they seriously evaluate, and most of the time that works out well. Some percentage of the time, the target the buyer wanted to close on has findings that make the deal not worth doing — and the value of a good diligence process is that it surfaces those findings before the buyer signs the LOI or, if post-LOI, before closing.
This post walks through the seven signals that a California treatment-business acquisition is a walk-away, not a workable deal. It is the third post in the buyer-diligence toolkit trio (with the pre-LOI ten questions and “what the seller isn’t telling you”) and the companion to Bay Legal’s practice-page conversion targets on acquisition compliance and remediation.
Key Takeaways
- Walking away from a bad target is a legitimate outcome of diligence. Some findings are administrative fixes, some change deal terms, and some are grounds to walk. The purpose of diligence is to distinguish.
- Seven signals suggest walking: historical exposure disproportionate to acquisition price; seller unwilling to accommodate structural changes CPOM diligence requires; physician-of-record unwilling to be the shareholder of the buyer’s new PC; marketing exposure requiring a wholesale rebuild the price cannot support; a pattern of bad-faith operation rather than compliance misunderstanding; an undisclosed pending investigation; and terms in the seller’s existing MSA the California AG has publicly identified as impermissible.
- Not every one of these signals is fatal in every deal. But any one of them meaningfully changes the price, the structure, or the timeline; the combination of two or more is typically dispositive.
- The California AG’s 2026 enforcement pattern (Aspen Dental, Carbon Health, the Art Center Holdings amicus brief) has raised the bar. Buyers who close on structures the AG has publicly labeled impermissible are taking on enforcement risk that is no longer theoretical.
The Seven Signals to Walk
Signal 1: Historical Exposure Disproportionate to Acquisition Price
What it looks like. The target has been operating a non-compliant structure for a substantial period — several years of LLC-based operation, direct patient billing, paper medical director, marketing overstating outcomes, or some combination. The historical exposure under B&P §§ 17200 (Unfair Competition Law), 17500 (false advertising), and the CPOM framework is meaningful. The buyer’s counsel can allocate the exposure to the seller through reps, warranties, indemnification, and escrow — but the seller’s net-of-payout price after the buyer’s escrow retention is more than the seller will accept, and the seller’s uncollateralized indemnification doesn’t provide meaningful buyer protection.
Why it’s a walk. The point of the historical exposure allocation is to give the buyer a clean going-forward structure and the seller a fair price. When the historical exposure is disproportionate to the acquisition price, the arithmetic doesn’t work: either the buyer takes the exposure without adequate protection, or the seller takes a price the seller won’t accept. Neither party has a workable deal.
What the buyer can do first before walking. Reprice the deal to account for the exposure and see whether the seller will accept. Restructure the acquisition to a smaller subset of assets (facility, brand, systems) without acquiring the operating entity or historical patient records. Extend the escrow period. If none of these produce a workable deal, walking is the answer.
Signal 2: Seller Won’t Accommodate Structural Changes CPOM Diligence Requires
What it looks like. Diligence surfaces that the target’s PC is not properly constituted, or the MSA needs a rebuild, or the good-faith exam workflow doesn’t meet the 2026 standard, or the standardized procedures manual is defective. The buyer’s counsel proposes structural changes as part of the closing transition. The seller refuses — either because the seller doesn’t accept the diligence finding, because the seller’s ongoing physician-of-record refuses to accommodate the changes, or because the seller has been advised by the seller’s counsel that the current structure is fine.
Why it’s a walk. If the buyer can’t restructure the target to be compliant post-closing, the buyer is buying a target that will remain non-compliant. The target’s problems become the buyer’s problems the day the deal closes. This isn’t a workable outcome regardless of price.
What the buyer can do first before walking. Escalate to a direct conversation between buyer’s counsel and seller’s counsel about the specific findings and the specific structural changes required. Offer to fund the physician-partner sourcing or MSA rebuild as part of the closing transition. Provide the seller with copies of the specific California AG enforcement materials (the Carbon Health settlement, the Aspen Dental settlement, the Art Center Holdings amicus brief) that establish the framework the buyer’s counsel is working from. If the seller still refuses after direct conversation and documentary evidence, the seller has told the buyer something important about how the seller will negotiate every post-closing question — and the buyer should walk.
Signal 3: Physician-of-Record Unwilling to Be the Shareholder of the Buyer’s New PC
What it looks like. The buyer’s structure requires a physician-partner to hold the newly formed professional corporation that will acquire the clinical assets. The seller’s current medical director is the obvious candidate — she knows the practice, has been the physician-of-record, and can transition without disrupting patient care. She is unwilling. Either because she wants to move to a different practice, because she disagrees with the buyer’s post-closing plans, because she isn’t willing to take on the compensation and clinical authority the shareholder role requires, or because she doesn’t want the exposure the shareholder role carries.
Why it can be a walk. The physician-partner is the load-bearing structural component of the friendly-PC + MSO acquisition. No physician-partner, no deal. Sourcing a new physician-partner from outside the target’s existing clinical staff is possible but adds meaningful time, expense, and clinical continuity risk to the closing transition. For some deals, the delay and disruption make the target no longer worth acquiring.
What the buyer can do first before walking. Direct conversation with the current medical director to understand the objection. Renegotiate the physician-partner compensation, buy-sell terms, or clinical authority to address the objection. Source an alternative physician-partner from outside the target’s staff (accepting the added time and continuity risk). Structure a transitional arrangement where the current medical director remains involved for a defined period during the search for a new shareholder. If none of these work, walking is legitimate.
Signal 4: Marketing Exposure Requiring a Wholesale Rebuild the Price Cannot Support
What it looks like. The target’s marketing is extensive, includes specific outcome claims for off-label indications, includes testimonials that overstate typical results, includes influencer content without appropriate disclosures, and has been the practice’s primary growth engine for years. The buyer’s counsel identifies a large percentage of the marketing content as B&P § 17500 or FTC exposure. Rebuilding the marketing from a defensible foundation would take a meaningful portion of the target’s brand equity offline and require investment approaching a significant fraction of the acquisition price.
Why it can be a walk. Marketing exposure is a specific category — separate from CPOM structural issues, separate from clinical incident exposure, separate from payor exposure. It travels with the target’s operating history. Buyers who close on a marketing-heavy target and then take the marketing offline lose the growth engine they were paying for. Buyers who keep the marketing running inherit the exposure. Neither is a good outcome. Where the marketing exposure and the rebuild cost together approach the value of what the buyer is acquiring, the deal doesn’t work.
What the buyer can do first before walking. Reprice the deal to reflect the rebuild cost and the lost brand value during the rebuild period. Structure the acquisition around the practice’s clinical operations and facility, leaving the trade name and marketing IP with the seller (so the buyer rebuilds under a new brand). If neither of these produces a workable deal, walking is the answer.
Signal 5: Pattern of Bad-Faith Operation, Not Compliance Misunderstanding
What it looks like. The seller’s non-compliance isn’t a good-faith error, an outdated structure the seller inherited from a previous owner, or reliance on advice the seller believed was correct. It is a pattern — the seller has previously operated other non-compliant practices, has been through enforcement contact in another jurisdiction, has structured the current target with features designed to obscure the CPOM issue (nominee shareholders, opaque intercompany transfers, sham medical director agreements), or has responded to diligence questions with material misrepresentations that the buyer’s counsel can verify against contradictory documentary evidence.
Why it’s a walk. Bad-faith operation is a fundamentally different category from compliance misunderstanding. The buyer’s diligence can allocate historical exposure from a compliance-misunderstanding target through reps and warranties, indemnification, and escrow — the seller’s disclosures were incomplete but not fraudulent. A bad-faith seller’s reps and warranties are worth less because the seller’s history suggests the seller will contest the reps in enforcement. And a bad-faith seller’s operational patterns often extend to whatever documentation the buyer will need to prove the reps: contradictory patient records, missing incident logs, altered chart notes. The buyer is often better off not doing the deal.
What the buyer can do first before walking. Direct conversation with the seller about the specific findings. Verify the specific discrepancies with documentary evidence before concluding that bad faith rather than misunderstanding is the pattern. Consult with the buyer’s counsel about the specific enforcement risk profile the pattern presents. Where the pattern is confirmed, walking is generally the right decision even if the target is otherwise attractive.
Signal 6: Undisclosed Pending Investigation
What it looks like. Diligence surfaces evidence of a pending Medical Board investigation, a BRN inquiry into an injecting RN, a DEA registration issue, an AG office contact, a DHCS licensure question, a payor audit, or a consumer complaint before a public agency — that the seller has not disclosed. The evidence might come from public records, from a conversation with the medical director, from a former employee, from a review of the seller’s counsel’s recent correspondence, or from a Google search for the seller’s name paired with regulatory terms.
Why it’s a walk. Undisclosed pending investigations are not administrative fixes. They are open matters with unknowable outcomes that could result in disciplinary action, civil penalties, criminal referral, or license restriction — any of which would affect the target’s operating history and the buyer’s post-closing position. A seller who has not disclosed a pending investigation has either (a) forgotten it (unlikely for a matter of any substance), (b) doesn’t understand it as material (concerning), or (c) is actively withholding it (disqualifying). None of these outcomes are compatible with a workable acquisition.
What the buyer can do first before walking. Confront the seller directly with the finding. If the seller acknowledges and provides full documentation and cooperation, the buyer can reconsider — but the acquisition timing has to accommodate resolution of the matter, and the deal documents need to allocate the exposure appropriately. If the seller denies or minimizes, walking is the answer.
Signal 7: Existing MSA Contains Terms the AG Has Publicly Identified as Impermissible
What it looks like. The target operates under an existing friendly-PC + MSO structure, and the MSA has been in place for some time. The buyer’s counsel reviews it against the California AG’s 2026 enforcement benchmarks — the Carbon Health settlement, the Aspen Dental settlement, the Art Center Holdings amicus brief — and finds one or more of the specific arrangements the AG has publicly labeled impermissible: assignable options over PC ownership; exclusive above-market financing; complete MSO authority over clinician hiring, firing, and compensation; MSO control over advertising, payor negotiations, and equipment selection; without-cause replacement triggers for the PC’s physician-owner; discretionary management fees; incentive programs tied to increased product or service volume.
Why it can be a walk. The AG has drawn a clear line on these features. A buyer acquiring the target and continuing to operate under the existing MSA is taking on the enforcement risk the AG has publicly telegraphed. Rebuilding the MSA is often possible — but requires the seller (or the seller’s physician-of-record) to agree to the rebuild, which is Signal 2 territory. Where the MSA cannot be rebuilt and the buyer would have to continue under the existing terms, the target isn’t a workable acquisition regardless of price.
What the buyer can do first before walking. Rebuild the MSA as part of the closing transition — the buyer’s counsel drafts a compliant replacement MSA, and the seller / current physician-of-record signs it at closing. Restructure the acquisition to leave the existing PC and existing MSA behind — the buyer’s new PC and new MSO acquire the clinical and non-clinical assets and start fresh. If neither works, walking is legitimate.
Combinations Are Typically Dispositive
Any one of the seven signals is a significant deal-changing event that meaningfully affects the price, the structure, or the timeline. Two or more together are typically dispositive.
The clearest example: a target with substantial historical exposure (Signal 1), a seller unwilling to accommodate structural changes (Signal 2), and an existing MSA containing impermissible AG-flagged terms (Signal 7). The three signals compound. The historical exposure needs allocation the seller won’t accept. The going-forward structure can’t be fixed. The MSA can’t be rebuilt. Nothing about this combination is workable, and the buyer’s diligence pays for itself by surfacing them before the LOI.
Another common combination: a physician-of-record unwilling to be the buyer’s shareholder (Signal 3) plus an undisclosed pending Medical Board investigation involving that physician (Signal 6). The pending investigation both explains the physician’s unwillingness and disqualifies the seller. The deal doesn’t survive the finding.
The Walk-Away Conversation
Walking away is easier to do at the LOI stage than after signing. Which is why the pre-LOI diligence exists.
At the LOI stage, walking is a simple communication: “Our diligence has surfaced findings that make this deal not workable for us. We’re withdrawing from the LOI discussion. Thank you for your time and consideration.” No renegotiation, no unwind, no lawyer letters.
Post-LOI, walking is harder — the buyer has to invoke a diligence termination right if one exists in the LOI, or has to walk without one and accept the consequences (loss of any deposit, potential exclusivity claims from the seller). Post-signing but pre-closing, walking is harder still, the buyer has to invoke a closing condition or accept the consequences of default. Post-closing, walking isn’t available; the buyer owns the target and its findings.
The walk-away conversation is easier the earlier it happens. That is one of the strongest arguments for pre-LOI diligence.
When to Bring Counsel Into the Walk-Away Analysis
Before the LOI is signed. Structuring the diligence to surface findings early, categorizing them (administrative / structural / disqualifying), and translating them into a decision framework is exactly what pre-LOI structural counsel does. The value of diligence isn’t confined to deals that close — a well-run diligence that produces a good walk-away decision is a valuable outcome.
Bay Legal, PC represents non-licensee buyers of California treatment businesses through pre-LOI structural counsel, CPOM diligence, and deal documentation. If your diligence is producing findings that suggest walking, we can help you assess whether the deal is workable, renegotiable, or a walk. Call (650) 668-8000 or schedule a consultation at baylegal.com/contact.
Frequently Asked Questions
Is walking away really a legitimate outcome? Doesn’t it mean the diligence failed?
Walking away is a legitimate outcome and often the right one. The purpose of diligence is to give the buyer accurate information about the target and to translate that information into a decision framework. A diligence process that produces a good walk-away decision has done its job — it has prevented the buyer from closing on a target that would not have worked. Buyers who close every deal they diligence are typically closing some deals they should have walked away from.
How do I distinguish a bad-faith seller from a seller who genuinely didn’t know their structure was non-compliant?
Documentary consistency is the primary test. A good-faith seller’s operational patterns, prior legal advice, marketing history, and diligence responses all tell a consistent story — the seller was operating under a compliance framework the seller believed was correct, even if the framework was wrong. A bad-faith seller’s story doesn’t hold together, the operational patterns contradict the seller’s diligence responses, the prior legal advice is characterized inconsistently, the marketing overstates something the seller now denies, and the seller’s responses to specific findings don’t align with the underlying documents. Bay Legal’s diligence framework includes cross-referencing that surfaces the inconsistency when it exists.
What if I’ve already signed the LOI and walking away means I lose my deposit?
This is a real cost, and it should be weighed against the cost of closing on a target that has surfaced disqualifying findings. Losing a $25,000 or $50,000 diligence deposit is a substantial hit, but it is meaningfully smaller than the historical exposure a buyer inherits by closing on a bad-faith seller’s non-compliant target. The buyer’s counsel can also help evaluate whether the LOI’s exclusivity or diligence termination provisions allow a walk-away without losing the deposit.
Are these seven signals the only reasons to walk?
No. These are the seven most common CPOM-specific signals in California treatment-business acquisitions. General M&A reasons to walk (financials that don’t hold up, tax exposure that can’t be allocated, employment claims that can’t be resolved, real estate title issues, undisclosed contract encumbrances) still apply and are additional reasons. The seven signals in this post are the healthcare-specific ones that general M&A diligence doesn’t surface.
What should I do if my diligence surfaces one signal but the target is otherwise very attractive?
Any of the seven signals is meaningful; not every one is fatal. The specific analysis depends on the signal and the specific facts. Historical exposure disproportionate to price (Signal 1) can sometimes be repriced or restructured to work. A seller resistant to structural changes (Signal 2) sometimes softens after direct conversation. An MSA with AG-flagged terms (Signal 7) can sometimes be rebuilt. The buyer’s counsel can help evaluate whether the specific signal is renegotiable or is a hard stop for this deal.
Talk to a California Healthcare Acquisition Attorney
Bay Legal, PC represents non-licensee buyers of California treatment businesses through pre-LOI structural counsel, CPOM diligence, and — where the diligence indicates it, walk-away analysis. If your diligence is producing findings that suggest walking, call (650) 668-8000 or schedule a consultation at baylegal.com/contact.
